Atom Bioscience Raises $45 Million In Series C Round Of Financing To Advance Development Of Small Molecule Drugs For Inflammatory And Metabolic Diseases

Jan 05, 2022•over 3 years ago

Amount Raised

$45 Million

Round Type

series c

Description

Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases such as chronic gout and non-alcoholic steatohepatitis (NASH), announced today the close of a $45 million Series C financing round to support a global Phase III clinical trial of ABP-671, the company’s lead small molecule drug for hyperuricemia and gout, and preclinical and clinical development of other pipeline products.

Company Information

Company

Atom Bioscience

About

Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co. Ltd.) is a fast-growing innovative drug company, focused on development of best in class small molecule therapeutics for treatment of inflammatory and metabolic diseases. The company’s lead product, ABP-671, is in clinical development for treatment of chronic gout. Another small molecule, ABP-6016, has shown remarkable potency for treatment of non-alcoholic steatohepatitis (NASH) with an excellent safety profile. For more information please visit: http://www.atombp.com/en/

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech